DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality

Cytokine release syndrome (CRS) immune effector cell–associated neurotoxicity syndrome are the most notable toxicities of CD19 chimeric antigen receptor (CAR) T-cell therapy. In addition, CAR T-cell–mediated toxicities can involve any organ system, with varied impacts on outcomes, depending on patie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Wudhikarn, Kitsada, Pennisi, Martina, Garcia-Recio, Marta, Flynn, Jessica R., Afuye, Aishat, Silverberg, Mari Lynne, Maloy, Molly A., Devlin, Sean M., Batlevi, Connie Lee, Shah, Gunjan L., Scordo, Michael, Palomba, Maria Lia, Dahi, Parastoo B., Sauter, Craig S., Santomasso, Bianca D., Mead, Elena, Perales, Miguel-Angel
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362382/
https://ncbi.nlm.nih.gov/pubmed/32614964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001972
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados